Related Experiment Video
Updated: Apr 7, 2026
06:26
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
2.1K
Biologics in dermatology: adverse effects
Virendra N Sehgal1, Deepika Pandhi2, Ananta Khurana3
1Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Delhi, India.
International Journal of Dermatology
|July 7, 2015
Summary
Biologic drugs offer targeted immune response modulation but require careful patient selection due to potential adverse effects. Understanding and managing these side effects is crucial for successful biologic therapy in dermatology.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Biologic drugs precisely target specific immune response pathways.
- Their use presents a double-edged sword, balancing clinical benefit with potential adverse effects.
- A cautious approach is necessary, emphasizing patient selection and knowledge of side effects.
Purpose of the Study:
- To list and outline adverse effects of commonly used biologics in dermatology.
- To explain plausible causes and incriminating factors of biologic-induced adverse reactions.
- To provide essential didactic content for practitioners on managing these side effects.
Main Methods:
- Review and compilation of adverse effects associated with prevalent dermatologic biologics.
- Succinct outlining of plausible mechanisms and causative factors for adverse reactions.
- Brief discussion on the management strategies for identified adverse effects.
Main Results:
- A comprehensive list of adverse effects for commonly used dermatologic biologics is presented.
- Plausible causes and contributing factors for these adverse reactions are clearly outlined.
- Management approaches for adverse effects are briefly detailed.
Conclusions:
- Successful use of biologics in dermatology hinges on careful patient selection and a thorough understanding of adverse effects.
- Knowledge of potential side effects, their causes, and management is essential for practitioners.
- A balanced approach is advocated to maximize clinical utility while minimizing risks associated with biologic therapies.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
357
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
357
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
775
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
775
01:29Inflammatory Bowel Disease IV: Pharmacological Management
967
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
967
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
698
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
698
01:30Drug Toxicity: Allergic Reactions
152
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
152
01:01Hypersensitivity Reactions: Cytolytic Reactions
135
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
135